TARGEDYS
About
Company description
TargEDys is a French biotech addressing overweight and control of appetite through the microbiome.
Its flagship product Satylia® is a precision probiotic food supplement based on the strain Hafnia alvei HA4597®, with a deeply characterized mechanism of action down to molecular level. It targets fullness pathways via ClpB, a human peptide analog (a-MSH) able to increase satiety hormone (PYY & GLP-1).
Hafnia alvei HA4597® efficacy was demonstrated in a randomized double-blind placebo-controlled clinical trial involving 230 overweight adults, published in Nutrients in 2021. Satylia® is already distributed in 8 countries and ready to market.
Since 2023, TargEDys is a subsidiary of Biocodex, a French pharmaceutical Group marketing the probiotic strain Saccharomyces Boulardii CNCM I-745, today No. 1 worldwide by value.
Quick facts
| Sales markets | Asia; Central/South America; Eastern Europe; Middle East; Western Europe |
|---|---|
| Primary business activity | Manufacturer: Finished Food Products |
| Affiliated categories: | Branded Finished Products |Food Supplements / Nutraceuticals |Postbiotics More |
